Synta - Exploring Galaxy And Beyond NASDAQ ... ovarian cancer and under a phase I trial for acute myeloid leukemia; STA-9584 under preclinical development for prostate cancer and CRACM channel inhibitors, also under preclinical testing for chronic inflammatory diseases and transplant rejection. |
